	US 12,465,587 B2
	Sulcardine administration for treatment of acute atrial fibrillation
Gary Elliott, San Diego, CA (US); Mireille Gillings, San Diego, CA (US); Robert Goodenow, San Diego, CA (US); Jay Mason, San Diego, CA (US); Waldemar Radziszewski, San Diego, CA (US); and Suzanne Romano, San Diego, CA (US)
Assigned to HUYABIO International, LLC, San Diego, CA (US)
Filed by HUYABIO INTERNATIONAL, LLC, San Diego, CA (US)
Filed on Oct. 11, 2023, as Appl. No. 18/484,823.
Application 18/484,823 is a continuation of application No. 17/345,564, filed on Jun. 11, 2021, granted, now 11,813,245.
Claims priority of provisional application 63/038,664, filed on Jun. 12, 2020.
Prior Publication US 2024/0058304 A1, Feb. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4025 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 9/06 (2006.01)

CPC A61K 31/4025 (2013.01) [A61K 9/0053 (2013.01); A61K 45/06 (2013.01); A61P 9/06 (2018.01)]

23 Claims

1. A method of causing a decrease in JTpc in a patient having cardiovascular disease, comprising administering to a patient a pharmaceutical composition comprising sulcardine or a pharmaceutically acceptable salt thereof, wherein the method causes a decrease in JTpc.